Bowu Chen
5 Papers
3 Citations
Bowu Chen is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Traditional Chinese Medicine JingYinGuBiao Formula Therapy Improves the Negative Conversion Rate of SARS-CoV2 in Patients with Mild COVID-19
Bowu Chen,Peihua Geng,Jiaojiao Shen,Suthat Liangpunsakul,H Y Lyu,Jue Zhang,Yanbing Yang,Lei Zhang,Yuping Xu,Chunling Dong,Yanping Wang,Yanning Xue,Wei Zhang,Huan Liu,Ma Li,Yueqiu Gao +15 more
TL;DR: JYGB, a TCM prescription, improves the negative conversion rate of SARS-CoV2 in mild COVID-19 patients and for patients with interval time ≤4 days or patients≤ 60 years, the clinical effects were more remarkable with an increase in cumulative negative conversion rates, a decrease in negative conversion time and hospitalized days.
Clinical efficacy of Jingyin granules, a Chinese patent medicine, in treating patients infected with coronavirus disease 2019
Bowu Chen,Xiaoxiao Yu,Lei Zhang,Wenqi Huang,H Y Lyu,Yuping Xu,Jiaojiao Shen,Weian Yuan,M Fang,Man Li,Yueqiu Gao +10 more
TL;DR: Jingyin granules (JY), one patented Chinese herbal formula, have been advised for treating coronavirus disease 2019 (COVID-19) in China as discussed by the authors , but the safety and effectiveness of JY in treating mild COVID19 patients were still to be evaluated.
9
Ancient Herbal Formula Mahuang Lianqiao Chixiaodou Decoction Protects Acute and Acute-on-Chronic Liver Failure via Inhibiting von Willebrand Factor Signaling
Jiacheng Lin,Qi-Hua Ling,Lin-li Yan,Bowu Chen,Fang Wang,Yi-Qi Qian,Yueqiu Gao,Qian Wang,Hailong Wu,Xue-Hua Sun,Yanjun Shi,Xiaoni Kong +11 more
TL;DR: In this article , MaHuang-LianQiao-ChiXiaoDou decoction (MHLQD) has been used clinically for centuries to treat liver diseases.
Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.
Zhuo Yu,Yan-Xin Zheng,Bowu Chen,Jia-Nan Lv,Xiaojun Zhu,Binyi Shang,Yuping Xv,Ru Tao,Yanbing Yang,Jun-zi Cong,Dan Li,Huan Wu,Wenchao Qv,Xiyi Zhang,Chengbin Xv,Hai Feng,Weian Yuan,Yueqiu Gao +17 more
TL;DR: This multi-arm trial assessed the efficacy and safety of Huashi Baidu granule, Paxlovid, and their combination in treating high-risk patients with Omicron variant COVID-19. Combination therapy showed increased efficacy and hospital discharging rates compared to monotherapies, with no severe adverse events.
2
Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial
TL;DR: Huashibaidu granule (HSBD) was used in treating mild Corona Virus Disease 2019 (COVID-19) patients infected with SARS-CoV-2 as discussed by the authors .
2